Introduction
The metabolic peptide landscape has expanded significantly in recent years, moving beyond the GLP-1 receptor agonist paradigm that brought semaglutide and tirzepatide to global prominence. Among the most closely watched emerging research targets is cagrilintide — a long-acting amylin analogue that represents a mechanistically distinct approach to metabolic research. Where GLP-1 agonists act primarily through incretin pathways to modulate insulin secretion and gastric emptying, cagrilintide targets the amylin receptor system, engaging complementary central and peripheral mechanisms that researchers believe may offer additive benefits when studied in combination.
Published research on cagrilintide — developed by Novo Nordisk under the research code AM833 — has focused on its pharmacokinetic profile, receptor selectivity, and effects in metabolic models. When combined with semaglutide in what researchers refer to as “CagriSema,” the compound pair has generated substantial interest in the metabolic research community, with Phase 2 and Phase 3 clinical trial data beginning to emerge in the primary literature.
This article provides an educational overview of cagrilintide — its mechanism of action, its relationship to the amylin system, the key published research on the CagriSema combination, and the questions that remain open for ongoing investigation. All information is presented for educational and research purposes only and does not constitute medical advice or treatment guidance.
The Amylin System: Background and Biology
To understand cagrilintide, it is essential to first understand the amylin system. Amylin (also known as islet amyloid polypeptide, or IAPP) is a 37-amino acid peptide co-secreted with insulin by pancreatic beta cells in response to nutrient intake. It acts on a family of receptors formed by the calcitonin receptor (CTR) in complex with receptor activity-modifying proteins (RAMPs), most notably RAMP1, RAMP2, and RAMP3. The CTR/RAMP1 complex constitutes the canonical amylin receptor (AMY1), while CTR/RAMP3 forms AMY3.
Amylin receptors are distributed in key metabolic tissues and brain regions. In the central nervous system, the area postrema and nucleus tractus solitarius express high levels of amylin receptors, positioning this system to regulate satiety signaling and energy homeostasis. Peripherally, amylin affects gastric motility, glucagon secretion, and nutrient absorption kinetics.
The physiological actions of amylin complement those of insulin: while insulin drives glucose uptake into peripheral tissues, amylin slows the rate of glucose appearance from the gut and suppresses post-prandial glucagon secretion — effectively providing a more gradual glycemic profile following meals. Research indicates that amylin signaling is impaired in metabolic disease states, making the amylin receptor axis a compelling research target.
The natural amylin peptide has limited utility as a research tool due to its tendency to form amyloid fibrils, which are associated with the amyloid deposits observed in the pancreatic islets of individuals with type 2 diabetes. Cagrilintide was engineered to overcome these limitations, with structural modifications designed to prevent fibril formation while maintaining and enhancing receptor agonist activity.
Cagrilintide: Mechanism of Action and Design
Cagrilintide is a fatty acid-acylated amylin analogue designed for once-weekly subcutaneous administration — a significant pharmacokinetic improvement over the native amylin peptide, which has a circulating half-life of only a few minutes. The acylation strategy (similar to that used in semaglutide’s design) facilitates binding to albumin in circulation, dramatically extending the effective half-life and enabling sustained receptor engagement.
Key structural features of cagrilintide include:
- Amyloid prevention: Multiple amino acid substitutions at positions critical for fibril formation in native IAPP, eliminating the aggregation liability that limits the use of natural amylin in research.
- Receptor selectivity: Cagrilintide maintains high-affinity binding at amylin receptors (AMY1 and AMY3) while retaining some activity at the calcitonin receptor, consistent with the pharmacological profile of other amylin analogues.
- Extended half-life: Published pharmacokinetic data from Phase 1 studies indicate a half-life of approximately one week, supporting once-weekly dosing in research protocols.
The central effects of cagrilintide are of particular research interest. Amylin receptor activation in the area postrema and hypothalamus appears to modulate the neural circuits governing satiety, food intake, and energy expenditure — through mechanisms that are at least partially distinct from GLP-1 receptor signaling, which acts primarily through vagal afferent pathways and the dorsal vagal complex.
Key Research Findings: CagriSema Studies
The most significant research attention on cagrilintide has focused on its combination with semaglutide — a pairing studied under the designation CagriSema. The rationale for combining these two peptides rests on their mechanistically complementary actions: GLP-1 receptor agonism (semaglutide) and amylin receptor agonism (cagrilintide) engage overlapping but non-identical neural and peripheral circuits, raising the hypothesis that combination therapy might produce additive or synergistic effects in metabolic research models.
Phase 2 Clinical Research
Lau et al. (2021) published a Phase 2 randomized controlled trial evaluating CagriSema in The Lancet (DOI: 10.1016/S0140-6736(21)01751-7). The study enrolled adults with overweight or obesity and randomized them to cagrilintide alone, semaglutide 2.4 mg alone, CagriSema at various doses, or placebo. At 32 weeks, participants receiving the highest dose of CagriSema achieved mean weight reductions substantially exceeding those observed with either monotherapy arm. The authors concluded that the combination merited advancement to Phase 3 investigation, describing the additive effects as consistent with the complementary mechanisms of action.
Phase 3: REDEFINE Program
The REDEFINE clinical trial program evaluates CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) in participants with overweight or obesity. REDEFINE 1, which enrolled over 3,400 participants, reported topline results in late 2024: participants receiving CagriSema achieved a mean body weight reduction of approximately 22.7% at 68 weeks, compared to approximately 8% for placebo — representing one of the largest weight reductions observed in a randomized metabolic research trial to date. Full publication of the complete dataset is anticipated in the peer-reviewed literature.
Metabolic Marker Research
Beyond body weight, research has characterized CagriSema’s effects on metabolic markers. Published data from Phase 2 trials indicate improvements in fasting glucose, HbA1c, lipid profiles, and blood pressure parameters in study populations. The mechanism by which combined amylin/GLP-1 receptor agonism produces these effects is an active area of investigation, with researchers examining contributions from reduced caloric intake, altered gastric emptying, central satiety signaling, and direct effects on glucagon secretion.
Comparison with Other Metabolic Peptides
Understanding where cagrilintide fits in the broader metabolic peptide research landscape requires comparison with the established GLP-1 and dual GIP/GLP-1 agonist frameworks.
vs. Semaglutide (GLP-1 Mono-agonist)
Semaglutide acts exclusively through GLP-1 receptors, producing robust effects on food intake and gastric emptying through vagal and central mechanisms. Published Phase 3 trial data (STEP program) demonstrated mean weight reductions of approximately 14.9% with semaglutide 2.4 mg over 68 weeks. Research data from CagriSema trials suggest that adding cagrilintide to semaglutide produces incremental weight reduction beyond what semaglutide achieves alone, consistent with the engagement of a distinct receptor system. For an in-depth review of semaglutide research, see our Semaglutide research guide.
vs. Tirzepatide (GIP/GLP-1 Dual Agonist)
Tirzepatide engages both GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors. Published SURMOUNT Phase 3 trial data demonstrated mean weight reductions of approximately 20.9% at the highest dose over 72 weeks — exceeding semaglutide monotherapy but in a similar range to emerging CagriSema data. The mechanistic distinction is important: tirzepatide’s GIP receptor component primarily enhances insulin secretion and may affect fat tissue directly, while cagrilintide’s amylin receptor component acts more centrally on satiety and meal-timing signals. Our Tirzepatide research guide covers this mechanism in detail.
vs. Retatrutide (Triple Agonist)
Retatrutide adds GCG (glucagon) receptor agonism to GIP and GLP-1 activity, creating a trimodal mechanism. Published Phase 2 data reported mean weight reductions of approximately 17.5% at 24 weeks — an unusually rapid trajectory that reflects the energy expenditure-promoting effects of glucagon receptor activation. Compared to CagriSema, retatrutide operates through a distinct receptor triad; whether the amylin axis confers additional benefits over the glucagon axis in metabolic research models remains an open question.
Research Applications and Considerations
Cagrilintide is available for legitimate preclinical and research purposes through qualified research suppliers. Researchers studying metabolic peptides, amylin receptor pharmacology, or the central regulation of energy homeostasis may incorporate cagrilintide into in vitro or in vivo research protocols.
Key considerations for research use include:
Receptor Characterization Studies
Cagrilintide’s defined binding profile at AMY1 and AMY3 receptors makes it a useful research tool for characterizing amylin receptor subtypes and their contributions to metabolic regulation. Radioligand binding assays and functional cAMP accumulation assays are commonly used to study amylin receptor pharmacology in vitro.
Combination Research Models
The CagriSema paradigm has validated the concept of combining mechanistically complementary metabolic peptides. Researchers may explore analogous combination approaches in animal models of metabolic disease, using cagrilintide as the amylin receptor agonist arm of multi-peptide research protocols.
Storage and Handling
As a fatty acid-acylated peptide, cagrilintide requires careful cold-chain management to maintain structural integrity. Lyophilized powder should be stored at -20°C in a desiccated environment. Reconstituted solutions should be aliquoted and stored at -80°C, with exposure to freeze-thaw cycles minimized. Acylated peptides can be sensitive to certain organic solvents; reconstitution in physiological buffer at near-neutral pH is standard practice.
CertaPeptides offers Cagrilintide (CP-CAG) for research purposes, along with our full range of metabolic research peptides.
Key Takeaways
- Cagrilintide is a long-acting amylin analogue that activates amylin receptors (AMY1, AMY3) through mechanisms distinct from GLP-1 and GIP receptor agonists, acting primarily through central satiety circuits in the area postrema and hypothalamus.
- Structural modifications — including amino acid substitutions to prevent fibril formation and fatty acid acylation for albumin binding — give cagrilintide a once-weekly pharmacokinetic profile suitable for sustained research studies.
- Published Phase 2 trial data (Lau et al., 2021, The Lancet) demonstrated that the CagriSema combination (cagrilintide + semaglutide) produced greater metabolic effects than either peptide alone, supporting the mechanistic complementarity hypothesis.
- Topline REDEFINE Phase 3 data reported approximately 22.7% mean body weight reduction with CagriSema at 68 weeks, among the largest reductions observed in randomized metabolic research trials.
- Cagrilintide occupies a distinct mechanistic niche from dual (tirzepatide) and triple (retatrutide) agonists, engaging the amylin axis rather than the GIP or glucagon receptor systems.
- Research applications include amylin receptor characterization, central energy homeostasis studies, and multi-peptide combination protocols in metabolic research models.
References
- Lau, D.C.W. et al. (2021). Once-weekly cagrilintide for weight management in adults with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled phase 2 trial. The Lancet, 398(10317), 2160–2172. DOI: 10.1016/S0140-6736(21)01751-7
- Enebo, L.B. et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg for weight management (CagriSema): a randomised, controlled, phase 1b trial. The Lancet, 397(10286), 1736–1748. DOI: 10.1016/S0140-6736(21)00845-X
- Wilding, J.P.H. et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 384(11), 989–1002. DOI: 10.1056/NEJMoa2032183
- Jastreboff, A.M. et al. (2023). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 388(13), 1199–1210. DOI: 10.1056/NEJMoa2301972
- Jastreboff, A.M. et al. (2023). Triple hormone receptor agonist retatrutide for obesity — a Phase 2 trial. New England Journal of Medicine, 389(6), 514–526. DOI: 10.1056/NEJMoa2301972
- Hay, D.L. et al. (2015). Amylin receptors: molecular composition and pharmacology. Biochemical Society Transactions, 43(3), 395–401. DOI: 10.1042/BST20140324
- Lutz, T.A. (2012). Control of energy homeostasis by amylin. Cellular and Molecular Life Sciences, 69(12), 1947–1965. DOI: 10.1007/s00018-011-0905-1
Disclaimer: This article is for educational and research purposes only. The information provided does not constitute medical advice and should not be interpreted as guidance for human use. Cagrilintide and related compounds are intended solely for laboratory research by qualified professionals. Always follow applicable regulations and institutional guidelines when conducting research. Consult qualified professionals before beginning any research protocol.